Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 6 - The Untold Story

Abbott reports strong earnings despite infant formula crisis

Abbott Laboratories reported strong earnings Wednesday, despite spending recent months responding to criticism over problems that led to the shutdown of one of its infant formula-producing plants.

Chicago Tribune

U.S. Stock Futures Edge Higher; Tesla Earnings In Focus

Pre-open movers

Benzinga

Is Abbott Stock a Buy at $105 as Production in Troubled Plant Resumes?

Leading healthcare company Abbott Laboratories (ABT) reported robust first-quarter results. And the company is well-positioned to benefit from its diversified business. Moreover, as ABT is resuming infant formula production at its Michigan facility, is the stock a good buy at the current price level? Read more to find out….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

This Biotech Stock Looks Like a Prime Growth Play

Diversified healthcare company Abbott (ABT) has demonstrated significant innovations across its segments, and given its dominant market position, the company’s prospects look bright. The stock could be a solid choice as it is well-positioned to survive short-term market fluctuations. Let’s discuss this in detail….

StockNews.com

What 6 Analyst Ratings Have To Say About Abbott Laboratories

Abbott Laboratories (NYSE:ABT) has observed the following analyst ratings within the last quarter:

Benzinga

Here's How Much $1000 Invested In Abbott Laboratories 5 Years Ago Would Be Worth Today

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 7.3% on an annualized basis producing an average annual return of 17.14%. Currently, Abbott Laboratories has a market capitalization of $187.96 billion.

Benzinga

This Top-Rated Healthcare Stock Is Trading at a 25% Discount

Medical device company Abbott Laboratories (ABT) reported impressive first-quarter results and affirmed its strong performance guidance for fiscal 2022. Furthermore, the company is well-positioned to benefit from its diversified business. However, amid the heightened market volatility, the stock is trading 25.5% below its 52-week high. So, the current dip in…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

FDA Probes Another Infant Death Given Abbott Formula, Less Than Month After Troubled Plant Reopens

Problems for Abbott Laboratories' (NYSE: ABT) Sturgis plant in Michigan for baby formula powder refuse to subside. The FDA was recently notified of another infant's death who was given formula made at Abbott's Sturgis facility.

Benzinga

FDA investigates death of another infant given Abbott formula

U.S. Food and Drug Administration officials are investigating the death of another infant who was given formula made by Abbott Laboratories.

Tribune News Service

Key US baby formula plant closes again as ‘torrential storms’ cause flooding

Production halt at Abbott Laboratories in Michigan will probably extend shortages for ‘a few weeks’

The Guardian - US

More Trouble For Baby Formula Production As Thunderstorms, Flood, Hit Abbott's Troubled Michigan Plant

Just a few weeks after reopening its baby formula Sturgis, Michigan plant, Abbott Laboratories (NYSE:ABT) said it paused EleCare specialty baby formula production after recent thunderstorms flooded part of the facility. The company has informed the FDA and will conduct comprehensive testing with an independent third party to ensure the plant is safe to…

Benzinga

5 Hard-Hit Large-Cap Stocks Ready to Rebound

The market turmoil this year, due to the sky-high inflation and the Fed’s hawkish tilt, has led several fundamentally solid large-cap stocks to trade below their intrinsic values. However, we believe quality large-cap stocks Broadcom (AVGO), Abbott (ABT), IQVIA (IQV), Agilent (A), and QUALCOMM (QCOM), which have declined significantly in…

StockNews.com

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,900 Today

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 2.54% on an annualized basis producing an average annual return of 14.5%. Currently, Abbott Laboratories has a market capitalization of $201.08 billion.

Benzinga

Analyzing Abbott Laboratories's Short Interest

Abbott Laboratories's (NYSE:ABT) short percent of float has risen 5.48% since its last report. The company recently reported that it has 13.46 million shares sold short, which is 0.77% of all regular shares that are available for trading.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Abbott Laboratories vs. Edwards Lifesciences: Which Medical Device Stock is a Better Investment?

The growing prevalence of chronic diseases, an increasing elderly population, and rapid adoption of advanced medical technologies are driving the growth of the medical device industry. The industry is expected to witness solid growth over the long term, to the benefit of the stocks of medical device companies Abbott (ABT)…

Benzinga

5 Analysts Have This to Say About Abbott Laboratories

Over the past 3 months, 5 analysts have published their opinion on Abbott Laboratories (NYSE:ABT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Reuters

Abbott reopens baby formula plant in Michigan

Abbott Laboratories said on Saturday that it has reopened its baby formula production plant in Sturgis, Michigan, taking a step toward alleviating an acute nationwide shortage that has sent parents scrambling for supplies.

The Guardian - AU

Australian company to ship baby formula to shortage-hit US

Joe Biden welcomes ‘good news’ as Bubs Australia increases production and reassures local customers

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 2.65% on an annualized basis producing an average annual return of 14.68%. Currently, Abbott Laboratories has a market capitalization of $203.74 billion.

Benzinga

Lawmakers Seek Answers From FDA, Abbott On Nationwide Baby Formula Shortage

FDA officials appeared before a congressional panel to answer questions about the crisis after Abbott Laboratories (NYSE: ABT) recalled some baby formula products and closed its manufacturing plant in Sturgis, Michigan.

The Guardian - UK

UK baby milk maker to fly formula to US to help ease shortages

Lake District-based Kendamil steps in after largest producer in US had nationwide recall

The Independent UK

Mother sues baby formula producer Abbott for child’s premature death

Suit claims Abbott Laboratories knew formula was risky for preterm infants

Salon

The baby formula scammers are here

Parents are being exploited by unscrupulous individuals, often in online spaces

Benzinga

Abbott's Troubled Baby Formula Michigan Plant To Reopen In 1-2 Weeks: Reuters

Abbott Laboratories (NYSE:ABT) and the FDA are reportedly on track to reopen the company's Sturgis, Michigan, baby formula manufacturing plant within one or two weeks, FDA Commissioner Robert Califf said. Abbott, the biggest U.S. supplier of powder infant formula, including Similac, agreed with the FDA on the steps needed to resume production at…

Tribune News Service

Viewpoint 3: To avoid the next infant formula crisis, make food safety a priority

The Food and Drug Administration has reached an agreement with Abbott Laboratories to resume production at the company’s Sturgis, Michigan, facility. The announcement gives hope of relief for the three-fourths of American parents who rely on infant formula, and have struggled to find the product in recent weeks.

1 … 5 6 7 8

People

Joe Biden

67,962 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.